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Abstract
Objective: To investigate longitudinally body mass index (BMI) evolution and obesity prevalence in a
large and very homogeneous study population consisting only of girls with non-organic central pre-
cocious puberty (CPP) who were treated with gonadotropin-releasing hormone agonists (GnRHa) for
at least two years.
Patients and design: The 101 girls with idiopathic CPP who were selected for this study fulfilled the
following inclusion criteria: (a) suppression of gonadotropin and gonadal sex steroid secretion
during the overall GnRHa treatment period; (b) adequate compliance with the therapy regimen.
All the girls were treated for 44^14 months and were followed-up for 15.7^7.8 months after
therapy withdrawal.
Results: At the start of therapy, 23.8% of the girls had a BMI exceeding 2 standard deviation scores
(SDS) and were therefore classified as obese; both average BMI-SDS and obesity prevalence signifi-
cantly decreased during the treatment period (x2 ¼ 16.6, P , 0.0005) and only 4% of the patients,
all with pre-existing obesity, were still obese at the end of therapy; during the therapy period, BMI-SDS
increased in none of the patients. Both average BMI-SDS and obesity prevalence (from 4 to 0%;
x2 ¼ 4.0, P , 0.05) further decreased during the period that followed therapy withdrawal.
Conclusions: (a) girls with idiopathic CPP are frequently obese at the onset of GnRHa therapy (23.8%),
probably due to the hormonal changes which accompany the start of puberty; (b) their obesity is
neither long-lasting nor related to GnRHa administration; (c) on the contrary, GnRHa therapy
may have a favourable effect on BMI decrease, provided that treatment is performed for at least
two years and is accompanied by a complete suppression of gonadotropin secretion; (d) this unex-
pected effect, which has never been reported hitherto, might represent a further indication for
GnRHa administration in idiopathic CPP.
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Introduction
Rapidly progressive forms of idiopathic central preco-
cious puberty (CPP) need to be treated because of the
psychosocial problems in the family and the affected
children (1) and because of the development of short
stature and associated body disproportion due to pre-
mature epiphyseal fusion (2).
Depot preparations of gonadotropin-releasing hor-
mone (GnRH) agonists (GnRHa) have become the treat-
ment of choice for CPP since the mid-1980s, although
follow-up investigations have shown different results
with regard to the effects and benefits of this therapy.
Much of the past research concerning the auxologi-
cal effects of treatment with GnRHa in CPP has focused
on the assessment of final height (3–8). Much less
attention has been paid to the changes in weight and
body composition. However, concerns have been
expressed that CPP may be associated with increased
body mass index (BMI) both at initial presentation
and during GnRHa treatment (9) and that this con-
dition may persist after therapy withdrawal, progres-
sing to frank obesity (10). The results of other studies
have confirmed that children with CPP are prone to
the development of obesity (7, 11), but this predilection
has not been demonstrated to be related to GnRHa
administration (12).
The aim of this prospective and multicentric study
was to investigate longitudinally BMI evolution and
obesity prevalence in a large cohort of girls with
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This prospective study covers 101 girls with idiopathic
CPP whose auxological and hormonal data at the start
of treatment and during follow-up are summarized in
Table 1. At treatment onset all patients had a history
of increased growth velocity (GV) and a breast develop-
ment of Tanner stage 2 or more (2.8^0.4). In all cases,
bone age (BA) was advanced more than one year
beyond chronological age (CA) and the average
BA:CA ratio was more than 1 (Table 1).
The main criteria for diagnosis of idiopathic CPP
have been: (a) onset of breast development and/or
menses before 8 years of age (mean 6.8^ 2 0.8,
range 3.1–7.8); (b) pubertal luteinizing hormone
(LH) response to exogenous GnRH (LH peak
.10 IU/l) (13); (c) a ratio of stimulated LH:stimulated
follicle-stimulating hormone (FSH) of more than 1.0
(14, 15); (d) no clinical signs and/or history of organic
CPP; (e) no evidence of hypothalamo –pituitary lesions
at magnetic resonance imaging (MRI); (f) no additional
conditions that might affect puberty onset and/or BMI
(e.g. primary hypothyroidism, congenital adrenal
hyperplasia or growth hormone deficiency).
The hormonal criteria for the assessment of pubertal
status have been established on the basis of inter-
national reports (13–15) and have been validated in
our department laboratories.
All the girls with idiopathic CPP who were selected
for the present study fulfilled the following inclusion
criteria: (a) suppression of gonadotropin and gonadal
sex steroid secretion throughout the overall period of
GnRHa treatment; (b) adequate compliance with the
GnRHa regimen, as judged by GV decrease, parental
report and record of medication administration.
Study design
After the initial evaluation, the patients received the
same therapy (decapeptyl depot, D-Trp6-GnRH,
IPSEN-Biotech, Milan, Italy) at a dose of 60mg/kg
i.m. every 28 days. Average CA at the start of treatment
was 7.5^0.9 years (range 3.3–8.9). The average time
interval between the first symptoms of early puberty
and the start of treatment was 8.5^6.2 months
(range 3–26 months). All the girls were treated for at
least 24 months (X 44^14; range 24–96) and were
followed for 15.7^7.8 months (range 6–42) after
therapy withdrawal. Before treatment initiation, the
patients underwent clinical, auxological (height,
weight, BMI, BA), hormonal and neuroradiological
evaluations. The hormonal examination at entry
included basal and GnRH-stimulated levels of gonado-
tropins and basal levels of 17-b estradiol (E2). Neuro-
radiological examination was based on MRI of the
hypothalamo –pituitary region. Auxological measure-
ments were again performed every 6–12 months
throughout the treatment period and during the
period which followed therapy withdrawal. Hormonal
suppression under GnRHa therapy was validated by
repeating the GnRH stimulation test three months
after the start of treatment and by measuring only
baseline gonadotropin and E2 concentrations every 6
months during treatment.
This study design was approved by our hospitals’
ethical committees and written consent was obtained
from the parents of patients.
Methods
Heights were measured with Harpenden stadiometers
(Holtain Ltd, Crymmith, UK) and compared with age-
matched reference values for girls (16). The same Tan-
ner’s reference values were used for the assessment of
weight, GV and pubertal stages (16). Bone age of all
the girls was assessed by the same investigator using
Table 1 Chronological age (CA), bone age (BA), BA:CA ratio, height (H), growth velocity (GV), weight (W), luteinizing hormone (LH)
and estradiol (E2) serum levels at the 1st examination (before therapy onset), at the 2nd examination (at the end of therapy period) and
at the 3rd examination (at the end of the entire follow-up period) in 101 girls with idiopathic CPP. n ¼ the number of cases at each
examination. Results are means^S.D.
1st examination (n ¼ 101) 2nd examination (n ¼ 101) P 3rd examination (n ¼ 101) P
CA (years) 75^0.9 11.2^0.9 12.4^0.7
BA (years) 9.8^1.2 12.4^0.5 13.6^0.6
BA:CA ratio 1.25^0.15 1.06^0.08 ,0.0005 1.02^0.06 ,0.0005
H-SDS 2.1^1.1 1.1^1.0 ,0.0005 20.7^0.8 ,0.0005
GV-SDS 1.6^1.0 21.3^2.0 ,0.0005 21.8^0.9 ,0.01
W-SDS 1.5^1.1 1.0^1.1 n.s. 20.6^0.8 ,0.005
LH (IU/l) 2.9^1.3 0.3^0.1 ,0.0005 2.3^1.5 ,0.0005
E2 (pmol/l) 78.3^41.2 24.2^6.1 ,0.0005 52.4^56.5 ,0.0005
Significance levels were calculated respectively between the 1st and the 2nd examination and between the 2nd and the 3rd examination. n.s., not
significant.
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an X-ray of the left hand, according to the method of
Greulich and Pyle (17).
The nutritional status of the patients during the over-
all study period was assessed by means of BMI, which
was calculated as weight (kg)/height (m2) and was
expressed in standard deviation scores (SDS), according
to the standards assessed by Rolland-Cachera et al.
(18). Serum LH, FSH and E2 were measured by the
same enzyme immunoassays (LH and FSH, Bioserv
Diagnostics, Rostock, Germany; E2, Research Diagnos-
tics Inc., Flanders, USA) in the four different local endo-
crine laboratories of our hospitals. The sensitivities of
the enzyme immunoassays were 0.3 IU/l for LH and
FSH and 15 pmol/l for E2. Values of 0.2 IU/l (for LH
and FSH) and 14 pmol/l (for E2) were assigned to the
sample below the detection limit. Pituitary–gonadal
axis function under treatment was considered as ade-
quately suppressed if LH and E2 values were main-
tained within the prepubertal normal ranges for our
laboratories, i.e. if: a) stimulated LH serum levels were
,5 IU/l; b) baseline LH levels were ,0.5 IU/l; and c)
E2 serum concentrations were ,50 pmol/l.
Statistical analyses
For statistical purposes, Student’s paired t-test, Wil-
coxon test, and chi-square test were used when appro-
priate in order to estimate differences between groups.
Correlations on individual values were made by Pear-
son’s test. All values are given as means^S.D.
Results
Auxological and hormonal data during
follow-up
The BA:CA ratio significantly and progressively
decreased from the 1st to the 3rd examination, as did
height and GV (Table 1).
During the same follow-up period, weight decrease
from the 2nd to the 3rd examination was highly signifi-
cant, whereas its reduction from the 1st to the 2nd
evaluation did not achieve statistical relevance
(Table 1).
As far as hormonal status is concerned both baseline
LH and E2 serum levels significantly decreased after the
onset of therapy, whereas a relevant rebound was
observed after GnRHa therapy withdrawal (Table 1).
BMI and obesity prevalence during follow-up
BMI and obesity prevalence data in the whole study
population during the entire follow-up period are sum-
marized in Table 2.
At the time of therapy initiation, the BMI-SDS was,
on average, very high and 24/101 patients (23.8%)
had a BMI exceeding 2 SDS and were therefore classi-
fied as obese.
BMI-SDS at the onset of therapy positively correlated
with both height-SDS (r ¼ 0.34, P , 0.001) and BA at
the same time-point (r ¼ 0.31, P , 0.01).
Both average BMI-SDS and obesity prevalence
(x2 ¼ 16.6, P , 0.0005) significantly decreased from
the 1st to the 2nd examination, i.e. at the end of the
treatment period (Table 2). The four girls with persist-
ing obesity were already obese at the onset of treat-
ment. Moreover, BMI-SDS did not increase during the
therapy period in any of the patients.
BMI-SDS at the end of treatment was positively
associated with BMI-SDS at entry (r ¼ 0.53,
P , 0.001) and negatively with treatment duration
(r ¼ 20.41, P , 0.001).
BMI-SDS and obesity prevalence (x2 ¼ 4.0,
P , 0.05) further decreased from the 2nd to the 3rd
examination, i.e. at the end of the entire follow-up
period (Table 2). During the overall study period (an
average of 60.2^10.1 months), the obesity prevalence
decreased from 23.8 to 0% (x2 ¼ 27.2, P , 0.0005)
and no girl at the end of the follow-up period was still
obese.
Finally, BMI-SDS at the end of the follow-up period
was positively related to both the initial BMI-SDS
(r ¼ 0.31, P , 0.01) and the value recorded at the
end of treatment (r ¼ 0.59, P , 0.001).
Discussion
The aims of the present study were to prospectively
evaluate whether obesity occurs at a high rate among
children with CPP, as reported in recent papers (12,
19), and whether a constantly and fully suppressed
hypothalamo –pituitary–gonadal axis in CPP may
have negative repercussions on the evolution af obesity,
as observed by other authors, especially in patients with
hypothalamic hamartoma (10).
In order to elucidate these two points, we have
put together a large and very homogeneous study
Table 2 Body mass index (BMI) and obesity prevalence at the 1st examination (before therapy onset), at the 2nd examination (at the
end of therapy period) and at the 3rd examination (at the end of the entire follow-up period) in 101 girls with idiopathic CPP. n ¼ the
number of cases at each examination.
1st examination (n ¼ 101) 2nd examination (n ¼ 101) P 3rd examination (n ¼ 101) P
BMI-SDS (mean^S.D.) 1.39^1.07 0.61^0.79 ,0.0005 0.11^0.52 ,0.0005
BMI (range) from 21.02 to 5.03 from 21.20 to 2.81 from 21.05 to 2.39
Obesity prevalence (%) 23.8 4.0 ,0.0005 0 ,0.05
Significance levels were calculated respectively between the 1st and the 2nd examination and between the 2nd and the 3rd examination.
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population consisting of only female subjects with idio-
pathic CPP, and have turned our specific attention to
the changes in weight and BMI that accompany a pro-
longed GnRHa administration (at least two years).
Only the girls who had exhibited a full and constant
pituitary –gonadal suppression under this treatment
were included in our study population.
Our results as a whole have confirmed that obesity is
a common problem in children with CPP (11, 20).
Indeed, in the present study a quarter of our patients
were found to be frankly obese before the institution
of therapy and only a few girls in the entire study popu-
lation had pre-treatment BMI-SDS lower than the aver-
age values for CA.
The reasons why so many girls with CPP have an
increased BMI at the start of therapy are not quite
clear. Unfortunately, we have insufficient data regard-
ing the subjects’ BMI before their exposure to a pubertal
sex steroid milieu. Nevertheless, it might be hypoth-
esized that BMI was already elevated at the time of pub-
erty onset in a fair proportion of our patients and this
may possibly have played a favourable role in CPP
development. According to Frisch’s ‘critical weight
hypothesis’, a certain percentage of body fat is needed
for the onset of menarche, and obese girls have earlier
menarche than thin girls (21, 22). Since BMI is a
reliable index of body fatness (23), it is not surprising,
therefore, that we and others (24) have found a signifi-
cant association between overweight and CPP before
therapy onset. This view is substantiated by the rel-
evant relationships found in our patients between
BMI and both height and BA at the 1st examination.
These findings suggest that both stature and BA were
more advanced at puberty onset in those girls with
the highest BMI.
In the last years, however, the ‘critical weight
hypothesis’ has been questioned and criticized (25,
26) and the current evidence linking fatness and pub-
ertal events do not confirm the direction of causation
that had been hypothesized by Frisch and Revelle
(21). On the contrary, according to the most recent
studies, it is the maturation timing that affects body
composition (27, 28), probably through the hormonal
changes associated with sexual maturation, which
promote the development of adipose tissue (24).
Our present results concerning the effects of GnRHa
treatment on the prevalence of obesity in girls with CPP
add new insights into this issue and provide additional
evidence for the influence of sexual maturation on
fatness. The suppression of pituitary–gonadal axis
function was accompanied in our series by a significant
decrease in overweightness. This suggests that
pre-treatment increase in BMI was due to the pubertal
hormonal changes and secondary changes in body fat,
rather than being a reason for CPP.
As it concerns the influences of GnRHa treatment on
the evolution of baseline overweight, the available data
in the literature are very controversial. According to
Heger et al. (19), obesity in CPP does not seem to be
either caused or aggravated by this treatment. Accord-
ing to the conclusions of Palmert et al. (11), the avail-
able data indicate that BMI in a population of
children with CPP does not change significantly
during GnRHa administration, although some individ-
uals may experience significant increases and decreases
during the course of therapy. The results of another
more recent study (12) demonstrate that, after an
initial aggravation of adiposity which follows GnRHa
therapy onset, no prolonged negative effects are detect-
able. Recently, Lazar et al. (29) have shown that GnRHa
administration causes a significant weight gain, if com-
pared with untreated patients. According to that
report, however, the weight gain caused by this treat-
ment is only temporary and should not be a reason
for sparing therapy (29).
In the present study, GnRHa therapy did not have a
negative impact on the evolution of baseline BMI in
any of the patients. On the contrary, in our series this
treatment was accompanied by a significant reduction
of adiposity, and only few patients, all with a pre-exist-
ing obesity, were still noted to be obese at therapy
withdrawal.
Ours is the first study that has been able to document
a reductive effect of GnRHa treatment on the preva-
lence of baseline obesity. It is to be reiterated, however,
that our investigation was based on a numerous and
very homogeneous patient cohort that included only
girls with non-organic CPP who were treated for at
least two years, i.e. a sufficiently prolonged therapy dur-
ation. This last point is very important, in the light of
the negative relationship found between BMI at treat-
ment withdrawal and therapy duration. This corre-
lation, in fact, suggests that a reduction of BMI under
GnRHa treatment may be observed only in those
cases who are treated for a long time.
Finally, our current data have demonstrated that
BMI further decreased and normalized after treatment
arrest and that none of the girls was still obese at the
last evaluation. A significant decrease of BMI two
years after cessation of treatment has also recently
been reported by van der Sluis et al. (12), although in
that report average BMI was still supranormal at the
end of follow-up.
To summarize, on the basis of our results we can
conclude that: (a) girls with idiopathic CPP may fre-
quently be obese at puberty onset probably due to the
hormonal changes which accompany the start of pub-
erty; (b) their obesity is neither long-lasting nor related
to GnRHa administration; (c) on the contrary, GnRHa
therapy may have a favourable effect on BMI decrease,
provided that treatment is performed for at least two
years and is accompanied by a complete suppression
of gonadotropin secretion; (d) this unexpected effect,
which has never been reported hitherto, might rep-
resent a further indication for GnRHa administration
in idiopathic CPP.
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